Abiopharma

🔍 MCKENZIE DIANA (Director)

Company: VERTEX PHARMACEUTICALS INC / MA (VRTX)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 943 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,174.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 796 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: D | equity_swap_involved: 0 | shares_owned_after: 2,378.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: Held in Trust | shares_owned_after: 207.00
• Acquired 796 shares of Deferred Stock Units (Derivative)
  Date: 2026-05-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 7,787.48 | transaction_form_type: 4 | Footnotes: F3, F2, F3, F3

Footnotes:

• F1: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
• F2: Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.
• F3: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.